← Back to Search

Continuous Glucose Monitoring Device

Continuous Glucose Monitoring for High Blood Sugar (CGM Trial)

Phase 1 & 2

Recruiting

Led By EILEEN FAULDS, PhD

Research Sponsored by Ohio State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with hyperglycemia (glucose >250mg/dl) or currently on IV insulin

Adults >18 years old admitted to Ohio State University Wexner Medical Center MICU

Must not have

Actively being treated for hyperosmolar non-ketoacidosis (HONK)

Refractory shock (Levophed dose >0.5 mcg/kg/min or equivalent)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up daily during micu admission; micu length of stay to be determined by patient medical needs

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing how well a new system for monitoring blood sugar works in patients in the hospital.

Who is the study for?

This trial is for adults over 18 in the MICU at Ohio State University Wexner Medical Center with high blood sugar or on IV insulin. It's not for those with severe shock, current COVID-19, high acetaminophen use, pregnancy, incarceration, DKA or HONK treatment, home insulin pump use during hospitalization, or certain skin conditions.

What is being tested?

The study tests if using a Dexcom G6 continuous glucose monitor (CGM) plus point-of-care testing can be feasibly implemented in critical care and how it affects nurse work patterns and patient outcomes compared to standard practices.

What are the potential side effects?

While CGMs like Dexcom G6 are generally safe and well-tolerated, potential side effects may include skin irritation where the device attaches to the body and inaccurate readings that could affect treatment decisions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have high blood sugar or am on IV insulin.

Select...

I am over 18 and admitted to the Ohio State University Wexner Medical Center MICU.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am currently receiving treatment for HONK.

Select...

I am experiencing severe shock requiring high doses of medication.

Select...

I am currently infected with COVID-19.

Select...

I am currently taking hydroxyurea.

Select...

I use an insulin pump at home and will continue to use it in the hospital.

Select...

I am currently receiving treatment for diabetic ketoacidosis.

Select...

I have swelling, skin discoloration, or severe swelling all over my body.

Select...

I have been taking more than 1 gram of acetaminophen every 6 hours.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ daily during micu admission; micu length of stay to be determined by patient medical needs

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~daily during micu admission; micu length of stay to be determined by patient medical needs

This trial's timeline: 3 weeks for screening, Varies for treatment, and daily during micu admission; micu length of stay to be determined by patient medical needs for reporting.